Could a class action lawsuit over Cymbalta be the first victim of Microsoft v. Baker?
Eli Lilly & Co. plans to move this month to dismiss a long-standing appeal in a case brought on behalf of a proposed class of consumers who used Cymbalta, an antidepressant prescription drug, according to a status report filed this week. The reason: Monday’s decision by the U.S. Supreme Court in Microsoft v. Baker, which blocked a controversial procedural tool that allowed plaintiffs to appeal class certification orders by dismissing their own case.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
